HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, 200 cGy TBI and Fludarabine; Postgrafting Immunosuppression Will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions
Most Recent Events
- 26 Jan 2021 Biomarkers information updated
- 03 Aug 2012 Additional lead trial investigator (Lauri Burroughs) identified as reported by University of Washington Health Sciences record.
- 03 Aug 2012 New source identified and integrated (University of Washington Health Sciences; 2032-00 ).